Summary
Emcure Pharmaceuticals reported a 36.2% increase in net profit and a 23% rise in revenue for the first quarter, alongside a 25.8% growth in EBITDA. The company also completed the acquisition of a minority stake in Gennova Biopharmaceuticals, starting its five-year plan strongly.